Back to UBS Group AG UBS Group AG

NVCTNVCT
Showing 8 of 17 quarters

Position history for UBS Group AGUBS Group AG's holdings in NUVECTIS PHARMA INC

UBS Group AG holds 69,200 shares of NVCT (NUVECTIS PHARMA INC), worth $1.3M as of 2026-Q2. The position was increased (+79.5% shares). NVCT represents 0.0% of UBS Group AG's portfolio.

Current Value

$1.3M

Current Shares

69,200

Total Value Change

+$1.3M

Total Shares Change

+69,189

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
69,200
+79.5%
$1.3M0.0%$18.39
39
2026-Q1
Increased
38,563
+360.4%
$298,0920.0%$8.71
26
2025-Q4
Decreased
8,375
-67.1%
$63,2310.0%$7.38
0
2025-Q3
Increased
25,469
+148.3%
$153,3230.0%$5.92
25
2025-Q2
Decreased
10,258
-90.8%
$76,6270.0%$7.55
0
2025-Q1
Increased
111,520
+4078.3%
$1.1M0.0%$10.46
41
2024-Q4
Increased
2,669
+242x
$14,4400.0%$5.14
20
2024-Q3
Decreased
11
-15.4%
$690.0%$6.18
0

Other major holders of NVCT: BlackRock, Inc., VANGUARD CAPITAL MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used